| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 751.47M | 723.22M | 677.29M | 639.34M | 565.55M | 471.44M |
| Gross Profit | 517.24M | 487.07M | 463.04M | 438.32M | 392.30M | 313.04M |
| EBITDA | 230.90M | 219.75M | 207.25M | 190.87M | 193.60M | 124.60M |
| Net Income | 151.18M | 140.72M | 130.31M | 118.33M | 125.34M | 89.48M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 1.01B | 928.71M | 891.75M | 825.21M | 668.02M |
| Cash, Cash Equivalents and Short-Term Investments | 155.28M | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M |
| Total Debt | 30.16M | 26.85M | 64.70M | 102.50M | 136.65M | 132.78M |
| Total Liabilities | 223.83M | 196.16M | 212.32M | 250.12M | 281.93M | 238.41M |
| Stockholders Equity | 822.94M | 815.73M | 716.39M | 641.63M | 543.28M | 429.62M |
Cash Flow | ||||||
| Free Cash Flow | 78.50M | 120.69M | 109.96M | 67.85M | 75.41M | 37.47M |
| Operating Cash Flow | 206.35M | 198.44M | 196.44M | 137.28M | 159.72M | 71.12M |
| Investing Cash Flow | -86.19M | -76.01M | -85.53M | -70.01M | -84.34M | -34.96M |
| Financing Cash Flow | -86.80M | -95.09M | -97.04M | -90.41M | -48.48M | -35.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr4.49B | 29.72 | 18.65% | 1.35% | 3.45% | 4.22% | |
| ― | kr6.28B | 210.07 | 1.32% | ― | 8.39% | -85.36% | |
| ― | €1.11B | 43.19 | 6.93% | ― | -5.80% | -65.99% | |
| ― | $1.66B | ― | -15.03% | ― | -21.56% | 70.41% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $932.29M | -6.14 | -35.36% | ― | 71.41% | 17.26% | |
| ― | €1.05B | -25.90 | -4.42% | ― | 13.48% | 28.98% |
CellaVision AB announced the release of its third-quarter 2025 report on November 6, inviting analysts, investors, and media to a conference call and webcast for a presentation by CEO Simon Østergaard. This event underscores the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
CellaVision has announced the formation of its Nomination Committee ahead of the 2026 Annual General Meeting, scheduled for April 28 in Lund. The committee, chaired by Joel Eklund, will propose candidates for key positions such as the Chairman of the General Meeting and members of the Board of Directors. This announcement is a routine part of CellaVision’s governance process, ensuring structured leadership and strategic planning for the company’s future operations.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
CellaVision has appointed Monica Jönsson as the Interim CFO, succeeding Magnus Blixt. Monica brings extensive experience from her previous roles, including her position as Group CFO at Perstorp Group. The company is in the process of recruiting a permanent CFO. This leadership change is expected to bring valuable expertise to CellaVision, potentially impacting its operations and market positioning positively.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK201.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.